Stop Flow in abdominal and pelvic cancer relapses

Rosario Vincenzo Iaffaioli; Gaetano Facchini; Anna Tortoriello; Feliciano Crovella; Giovannni Romano; Roberta Formato; Michele Santangelo; Emiddio Barletta; Francesco Fiore; Vittorio Iaccarino; Bruno Memoli; Roberto D'Angelo; Pier Luigi Pilati; Riccardo Rossi; Stefano Guadagni; Marcello Deraco; Sandro Pignata; Bruno Daniele; Gerardo Rosati; Bruno Massidda; Giovanni Mantovani; Enrico Di Salvo; Nicola Marzano; Vincenzo Memeo; Valerio Parisi; Giorgio Mallarini; Giuseppe Colucci

Stop Flow in abdominal and pelvic cancer relapses

Rosario Vincenzo Iaffaioli, Gaetano Facchini, Anna Tortoriello, Feliciano Crovella, Giovannni Romano, Roberta Formato, Michele Santangelo, Emiddio Barletta, Francesco Fiore, Vittorio Iaccarino, Bruno Memoli, Roberto D'Angelo, Pier Luigi Pilati, Riccardo Rossi, Stefano Guadagni, Marcello Deraco, Sandro Pignata, Bruno Daniele, Gerardo Rosati, Bruno MassiddaGiovanni Mantovani, Enrico Di Salvo, Nicola Marzano, Vincenzo Memeo, Valerio Parisi, Giorgio Mallarini, Giuseppe Colucci

Research output: Contribution to journal › Article › peer-review

Abstract

To determinate MTD, DLT and safe doses for phase II study, a dose finding study with Mitomicyn and Adriamycin Stop-Flow administration was carried out. A phase II study focused on resectability of pelvic colorectal relapses is in progress. From November 1995, 84 pts, 52 male and 32 female (94 treatments), with advanced not resectable abdominal (14 pts) or pelvic (70 pts) relapses, and resistant to previous systemic chemotherapy, were enrolled in the study. 46 pts entered the phase I-early phase II study, while subsequently 38 pts were recruited in ongoing phase II study. Safe dose were: MMC 20 mg/mq and ADM 75 mg/mq. The phase II study focused on colorectal relapses registered very promising responses: 90% pain control, 1 pCR and 26 PR/63 (OR 43%), 8 NC (13%) 9/27 responder patients (33%) obtained a complete resectability of colorectal relapses. Stop-Flow is a safe and feasible technique very useful as a palliation treatment.

Original language	English
Pages (from-to)	1284-1288
Number of pages	5
Journal	Frontiers in Bioscience
Volume	11
Issue number	2 P.1199-1590
Publication status	Published - 2006

Keywords

Cancer
Neoplasm
Pelvic relapses
Pelvis
Recurrence
Relapses
Stop-flow
Tumor

ASJC Scopus subject areas

Biochemistry, Genetics and Molecular Biology(all)
Biochemistry
Cell Biology

Cite this

Iaffaioli, R. V., Facchini, G., Tortoriello, A., Crovella, F., Romano, G., Formato, R., Santangelo, M., Barletta, E., Fiore, F., Iaccarino, V., Memoli, B., D'Angelo, R., Pilati, P. L., Rossi, R., Guadagni, S., Deraco, M., Pignata, S., Daniele, B., Rosati, G., ... Colucci, G. (2006). Stop Flow in abdominal and pelvic cancer relapses. Frontiers in Bioscience, 11(2 P.1199-1590), 1284-1288.

Iaffaioli, RV, Facchini, G, Tortoriello, A, Crovella, F, Romano, G, Formato, R, Santangelo, M, Barletta, E, Fiore, F, Iaccarino, V, Memoli, B, D'Angelo, R, Pilati, PL, Rossi, R, Guadagni, S, Deraco, M , Pignata, S, Daniele, B, Rosati, G, Massidda, B, Mantovani, G, Di Salvo, E, Marzano, N, Memeo, V, Parisi, V, Mallarini, G & Colucci, G 2006, 'Stop Flow in abdominal and pelvic cancer relapses', Frontiers in Bioscience, vol. 11, no. 2 P.1199-1590, pp. 1284-1288.

@article{39a44d5fb4764e58b232627116b88add,

title = "Stop Flow in abdominal and pelvic cancer relapses",

abstract = "To determinate MTD, DLT and safe doses for phase II study, a dose finding study with Mitomicyn and Adriamycin Stop-Flow administration was carried out. A phase II study focused on resectability of pelvic colorectal relapses is in progress. From November 1995, 84 pts, 52 male and 32 female (94 treatments), with advanced not resectable abdominal (14 pts) or pelvic (70 pts) relapses, and resistant to previous systemic chemotherapy, were enrolled in the study. 46 pts entered the phase I-early phase II study, while subsequently 38 pts were recruited in ongoing phase II study. Safe dose were: MMC 20 mg/mq and ADM 75 mg/mq. The phase II study focused on colorectal relapses registered very promising responses: 90% pain control, 1 pCR and 26 PR/63 (OR 43%), 8 NC (13%) 9/27 responder patients (33%) obtained a complete resectability of colorectal relapses. Stop-Flow is a safe and feasible technique very useful as a palliation treatment.",

keywords = "Cancer, Neoplasm, Pelvic relapses, Pelvis, Recurrence, Relapses, Stop-flow, Tumor",

author = "Iaffaioli, {Rosario Vincenzo} and Gaetano Facchini and Anna Tortoriello and Feliciano Crovella and Giovannni Romano and Roberta Formato and Michele Santangelo and Emiddio Barletta and Francesco Fiore and Vittorio Iaccarino and Bruno Memoli and Roberto D'Angelo and Pilati, {Pier Luigi} and Riccardo Rossi and Stefano Guadagni and Marcello Deraco and Sandro Pignata and Bruno Daniele and Gerardo Rosati and Bruno Massidda and Giovanni Mantovani and {Di Salvo}, Enrico and Nicola Marzano and Vincenzo Memeo and Valerio Parisi and Giorgio Mallarini and Giuseppe Colucci",

year = "2006",

language = "English",

volume = "11",

pages = "1284--1288",

journal = "Frontiers in Bioscience - Landmark",

issn = "1093-9946",

publisher = "Frontiers in Bioscience",

number = "2 P.1199-1590",

}

TY - JOUR

T1 - Stop Flow in abdominal and pelvic cancer relapses

AU - Iaffaioli, Rosario Vincenzo

AU - Facchini, Gaetano

AU - Tortoriello, Anna

AU - Crovella, Feliciano

AU - Romano, Giovannni

AU - Formato, Roberta

AU - Santangelo, Michele

AU - Barletta, Emiddio

AU - Fiore, Francesco

AU - Iaccarino, Vittorio

AU - Memoli, Bruno

AU - D'Angelo, Roberto

AU - Pilati, Pier Luigi

AU - Rossi, Riccardo

AU - Guadagni, Stefano

AU - Deraco, Marcello

AU - Pignata, Sandro

AU - Daniele, Bruno

AU - Rosati, Gerardo

AU - Massidda, Bruno

AU - Mantovani, Giovanni

AU - Di Salvo, Enrico

AU - Marzano, Nicola

AU - Memeo, Vincenzo

AU - Parisi, Valerio

AU - Mallarini, Giorgio

AU - Colucci, Giuseppe

PY - 2006

Y1 - 2006

N2 - To determinate MTD, DLT and safe doses for phase II study, a dose finding study with Mitomicyn and Adriamycin Stop-Flow administration was carried out. A phase II study focused on resectability of pelvic colorectal relapses is in progress. From November 1995, 84 pts, 52 male and 32 female (94 treatments), with advanced not resectable abdominal (14 pts) or pelvic (70 pts) relapses, and resistant to previous systemic chemotherapy, were enrolled in the study. 46 pts entered the phase I-early phase II study, while subsequently 38 pts were recruited in ongoing phase II study. Safe dose were: MMC 20 mg/mq and ADM 75 mg/mq. The phase II study focused on colorectal relapses registered very promising responses: 90% pain control, 1 pCR and 26 PR/63 (OR 43%), 8 NC (13%) 9/27 responder patients (33%) obtained a complete resectability of colorectal relapses. Stop-Flow is a safe and feasible technique very useful as a palliation treatment.

AB - To determinate MTD, DLT and safe doses for phase II study, a dose finding study with Mitomicyn and Adriamycin Stop-Flow administration was carried out. A phase II study focused on resectability of pelvic colorectal relapses is in progress. From November 1995, 84 pts, 52 male and 32 female (94 treatments), with advanced not resectable abdominal (14 pts) or pelvic (70 pts) relapses, and resistant to previous systemic chemotherapy, were enrolled in the study. 46 pts entered the phase I-early phase II study, while subsequently 38 pts were recruited in ongoing phase II study. Safe dose were: MMC 20 mg/mq and ADM 75 mg/mq. The phase II study focused on colorectal relapses registered very promising responses: 90% pain control, 1 pCR and 26 PR/63 (OR 43%), 8 NC (13%) 9/27 responder patients (33%) obtained a complete resectability of colorectal relapses. Stop-Flow is a safe and feasible technique very useful as a palliation treatment.

KW - Cancer

KW - Neoplasm

KW - Pelvic relapses

KW - Pelvis

KW - Recurrence

KW - Relapses

KW - Stop-flow

KW - Tumor

UR - http://www.scopus.com/inward/record.url?scp=32844464471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32844464471&partnerID=8YFLogxK

M3 - Article

C2 - 16368515

AN - SCOPUS:32844464471

SN - 1093-9946

VL - 11

SP - 1284

EP - 1288

JO - Frontiers in Bioscience - Landmark

JF - Frontiers in Bioscience - Landmark

IS - 2 P.1199-1590

ER -

Stop Flow in abdominal and pelvic cancer relapses

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this